Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17796355 | 1.00 | POLB (0.37) | POLBCYP2C19RETHTTSMN1; SMN2 | |
| SCHEMBL972122 | 0.78 | POLB (0.38) | POLBCYP2C19HTTSMN1; SMN2KDM4E | |
| SCHEMBL972124 | 0.78 | POLB (0.38) | POLBCYP2C19HTTSMN1; SMN2KDM4E | |
| SCHEMBL17796722 | 0.74 | ALDH1A1 (0.34) | POLBCYP2C19HTTSMN1; SMN2KDM4E | |
| SCHEMBL17796721 | 0.74 | ALDH1A1 (0.34) | POLBCYP2C19HTTSMN1; SMN2KDM4E | |
| SCHEMBL14108169 | 0.74 | — | — | |
| SCHEMBL20419546 | 0.69 | KDM4E (0.42) | KDM4EALDH1A1 | |
| SCHEMBL12569915 | 0.66 | — | — | |
| SCHEMBL19992372 | 0.65 | — | — | |
| SCHEMBL18529372 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | POLB 3483/4885CYP2C19 3337/4885RET 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.